| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 61.16B | 56.33B | 54.32B | 58.05B | 56.20B | 45.80B |
| Cost of revenue | 18.20B | 16.90B | 20.41B | 17.41B | 17.45B | 15.39B |
| Gross profit | 42.96B | 39.43B | 33.90B | 40.64B | 38.75B | 30.42B |
| Research and development | 9.10B | 12.79B | 7.67B | 6.51B | 6.92B | 6.38B |
| Selling, general and admin | 14.01B | 14.75B | 12.87B | 15.26B | 12.35B | 11.30B |
| Operating expenses | 46.09B | 47.20B | 41.56B | 39.94B | 38.27B | 34.44B |
| Operating income | 15.07B | 9.14B | 12.76B | 18.12B | 17.92B | 11.36B |
| EBITDA | 15.84B | 9.90B | 13.51B | 18.89B | 18.73B | 12.03B |
| Interest expense | 2.89B | 2.81B | 2.22B | 2.23B | 2.42B | 2.45B |
| Income before tax | 6.60B | 3.72B | 6.25B | 13.48B | 12.99B | 3.40B |
| Income tax | 2.36B | -570.00M | 1.38B | 1.63B | 1.44B | -1.22B |
| Net income | 4.23B | 4.28B | 4.86B | 11.84B | 11.54B | 4.62B |
| EPS | 2.37 | 2.40 | 2.73 | 6.65 | 6.48 | 2.73 |
| EPS (diluted) | 2.36 | 2.39 | 2.72 | 6.63 | 6.45 | 2.72 |
| Diluted shares | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.67B |
| Dividends per share | 6.65 | 6.29 | 5.99 | 5.71 | 5.31 | 4.84 |
From AbbVie's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.